Pharmacotherapy for Schizophrenic Drug Users - 6

This study has been completed.
Sponsor:
Collaborators:
VA Connecticut Healthcare System
Information provided by (Responsible Party):
Yale University
ClinicalTrials.gov Identifier:
NCT00000281
First received: September 20, 1999
Last updated: July 24, 2013
Last verified: December 2002
  Purpose

The purpose of this study is to evaluate maintenance neuroleptics for Schizophrenic patients who are cocaine abusers.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
Behavioral: Amantadine
Phase 2

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Pharmacotherapy for Schizophrenic Drug Users

Resource links provided by NLM:


Further study details as provided by Yale University:

Primary Outcome Measures:
  • Drug use
  • Retention
  • Psychological symptoms
  • Schizophrenic symptoms

Estimated Enrollment: 0
Study Start Date: September 1994
Study Completion Date: August 1999
Primary Completion Date: August 1999 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00000281

Locations
United States, Connecticut
VA Connecticut Healthcare System
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
Yale University
VA Connecticut Healthcare System
Investigators
Principal Investigator: Thomas R Kosten, M.D. VA Connecticut Healthcare System
  More Information

No publications provided

Responsible Party: Yale University
ClinicalTrials.gov Identifier: NCT00000281     History of Changes
Other Study ID Numbers: NIDA-09250-6, P50DA009250, P50-09250-6
Study First Received: September 20, 1999
Last Updated: July 24, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Amantadine
Antiparkinson Agents
Anti-Dyskinesia Agents
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Antiviral Agents
Anti-Infective Agents
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents

ClinicalTrials.gov processed this record on April 17, 2014